IP Library Granted Patent US 9,283,178
Granted Patent B2
US 9,283,178 · App. 14/481,778 · Granted Mar 15, 2016

Methods for treating edema in the eye and intraocular implants for use therefor

Inventor: Vernon G. Wong (Menlo Park, CA)
Assignee: Allergan, Inc.
A61K9/0051A61F9/0008A61F9/0017A61K9/0048A61K9/1641A61K9/1647A61K31/56A61K31/573A61K31/715A61K31/765A61K45/06A61K47/34A61L27/54A61F2210/0004A61L2300/222A61L2300/41A61L2300/416A61L2300/604
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,283,178
App. No.
14/481,778
Granted
Mar 15, 2016
Kind
B2
Abstract

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Claims (6)

1. A method for treating edema in an eye of an individual in need thereof, comprising: placing a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer in an eye of an individual, thereby treating edema of the eye of the individual, wherein the immunosuppressive agent comprises about 50% by weight to about 80% by weight of the drug delivery system, based on the total weight of the drug delivery system.

2. The method of claim 1 , wherein the biodegradable drug delivery system is placed in the vitreous of the eye.

3. The method of claim 1 , wherein the bioerodible polymer comprises a polylactic acid polyglycolic acid (PLGA) copolymer.

4. The method of claim 1 , wherein the bioerodible drug delivery system delivers the immunosuppressive agent for at least 5 days.

5. The method of claim 1 , wherein the bioerodible drug delivery system delivers the immunosuppressive agent for at least about 3 weeks.

6. The method of claim 1 , wherein the immunosuppressive agent comprises dexamethasone.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2015
From: WONG, VERNON G.
To: OCULEX PHARMACEUTICALS, INC.
Reel/Frame 034745/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2015
From: OCULEX PHARMACEUTICALS, INC.
To: ALLERGAN, INC.
Reel/Frame 034745/0755 →
Continuity (10)
Continuation 13871214 · Apr 26, 2013
Continuation 13296957 · Nov 15, 2011
Continuation 11852223 · Sep 7, 2007
Division 11738409 · Apr 20, 2007
Division 11180079 · Jul 11, 2005
Continuation 10744560 · Dec 22, 2003
Continuation 09997094 · Nov 28, 2001
Provisional Application 60250023 · Nov 29, 2000
Provisional Application 60298253 · Jun 12, 2001
Related Publication 20150005272A1 · Jan 1, 2015